News|Articles|February 20, 2020

UK Government Designates Harwell Campus as Opportunity Zone

The Office for Life Sciences of the government of the United Kingdom has designated six new locations in the country as ‘Life Sciences Opportunity Zones’, of which the Harwell Science and Innovation Campus is one.

The Office for Life Sciences of the government of the United Kingdom has designated six new locations in the country as ‘Life Sciences Opportunity Zones’, of which the Harwell Science and Innovation Campus is one.

In a Feb. 20, 2020 press release, Harwell revealed that this designation is one of only seven across the whole country and the only one in Oxfordshire/Thames Valley area. The designations are valid for a period of 10 years and will see the UK government working with Harwell to attract both inward and foreign investment, establish trade agreements, and promote the campus as a world-leading location for companies to establish themselves.

“The life sciences industry contributes over £70 billion [US $90.4 billion] per annum to the UK economy and provides 240,000 jobs. Harwell Campus plays an increasingly important role at the center of this sector,” said Gordon Duncan, partner, Harwell Science and Innovation Campus, in the press release. “We have a unique platform here to help accelerate research and innovation around the country, taking applied research and turning it into commercial outputs using state-of-the-art technologies and applications-this is unparalleled across Europe.”

Source: Harwell

 


Related to this article

Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation. | Image Credit: ©HockleyMedia24/peopleimages.com -stock.adobe.com
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Complying with International Pharmacopoeias
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.